gastric emptying glp-1 Glucagon-like peptide-1 (GLP-1) receptor agonists are incretin analogues that promote glucose-mediated insulin release and are used to treat type 2 diabetes mellitus and #obesity. receptor agonists and GLP-1 and glucose-dependent insulinotropic Support for Patients on GLP-1

Many successful outcomes involve gradual rather than dramatic initial changes

Take home points: Empagliflozin has a large study that shows a small but significant reduction in death and heart failure hospitalizations (NNT for primary outcome = 63 patients for ~3 years) compared to placebo in patients with diabetes and CV disease Empagliflozin can cause urinary and genital infections and ketoacidosis with near normal glucose Because of its mechanism (spilling glucose through the urine), it may develop a role in diabetes mellitus type 1 Refrences: American Diabetes Association: Standards of medical care in diabetes - 2016

Even with these strategies, it can still be difficult to ensure ALS patients get enough nutrition, especially as their condition worsens and metabolism continues to change

Behavioural and psychological support can significantly enhance weight management efforts